Table IV. Neutrophil to lymphocyte ratio (NLR) change during lenvatinib treatment for radioactive iodine ablation refractory differentiated thyroid cancer (RR-DTC) patients according to tumor response.

PR: Partial response; SD: stable disease; PD: progressive disease; NE: not evaluated; CI: confidence interval.